SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-025012
Filing Date
2021-05-06
Accepted
2021-05-06 16:22:05
Documents
66
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q eigr-10q_20210331.htm   iXBRL 10-Q 2154384
2 EX-10.2 eigr-ex102_260.htm EX-10.2 69317
3 EX-31.1 eigr-ex311_7.htm EX-31.1 16839
4 EX-31.2 eigr-ex312_8.htm EX-31.2 16903
5 EX-32.1 eigr-ex321_6.htm EX-32.1 5739
  Complete submission text file 0001564590-21-025012.txt   7870513

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA eigr-20210331.xsd EX-101.SCH 55023
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE eigr-20210331_cal.xml EX-101.CAL 54540
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE eigr-20210331_def.xml EX-101.DEF 146494
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigr-20210331_lab.xml EX-101.LAB 409810
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigr-20210331_pre.xml EX-101.PRE 304773
11 EXTRACTED XBRL INSTANCE DOCUMENT eigr-10q_20210331_htm.xml XML 1452964
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36183 | Film No.: 21898149
SIC: 2836 Biological Products, (No Diagnostic Substances)